Bernhard. J. Hering

Bernhard. J. Hering

Auto-generated profile, based on publicly available information

Bernhard. J. Hering

Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2016 in Diabetes Care
Verified
Journal Article
Open access
PDF file
BHBernhard J. Hering
Bernhard J. Hering
WCWilliam R. Clarke
William R. Clarke
NBNancy D. Bridges
Nancy D. Bridges
TEThomas L. Eggerman
Thomas L. Eggerman
RARodolfo Alejandro
Rodolfo Alejandro
FCfor the Clinical Islet Transplantation Consortium
for the Clinical Islet Transplantation Consortium
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.

16 February 2005 in JAMA
Verified
Journal Article
Closed access
PDF file
BHBernhard J. Hering
Bernhard J. Hering
RKRaja Kandaswamy
Raja Kandaswamy
JAJeffrey D. Ansite
Jeffrey D. Ansite
PEPeter M. Eckman
Peter M. Eckman
MNMasahiko Nakano
Masahiko Nakano
DSDavid E. R. Sutherland
David E. R. Sutherland
Research from JAMA — Single-Donor, Marginal-Dose Islet Transplantation in Patients With Type 1 Diabetes — ContextIslet allografts from 2 to 4 donors can reverse type 1 diabetes. However, for islet transplants to become a widespread clinical reality, diabetes reversal must be achieved with a single donor to reduce risks and costs and increase the availability of transplantation.ObjectiveTo assess the safety of a single-donor, marginal-dose islet transplant protocol using potent induction immunotherapy and less diabetogenic maintenance immunosuppression in recipients with type 1 diabetes. A secondary objective was to assess the proportion of islet transplant recipients who achieve insulin independence in the first year after single-donor islet transplantation.Design, Setting, and ParticipantsProspective, 1-year follow-up trial conducted July 2001 to August 2003 at a single US center and enrolling 8 women with type 1 diabetes accompanied by recurrent hypoglycemia unawareness or advanced secondary complications.InterventionsStudy participants underwent a primary islet allotransplant with 7271 (SD, 1035) islet equivalents/kg prepared from a single cadaver donor pancreas. Induction immunosuppression was with antithymocyte globulin, daclizumab, and etanercept. Maintenance immunosuppression consisted of mycophenolate mofetil, sirolimus, and no or low-dose tacrolimus.Main Outcome MeasuresSafety (assessed by monitoring the severity and duration of adverse events) and efficacy (assessed by studying the recipients’ insulin requirements, C-peptide levels, oral and intravenous glucose tolerance results, intravenous arginine stimulation responses, glycosylated hemoglobin levels, and hypoglycemic episodes) associated with the study transplant protocol.ResultsThere were no serious, unexpected, or procedure- or immunosuppression-related adverse events. All 8 recipients achieved insulin independence and freedom from hypoglycemia. Five remained insulin-independent for longer than 1 year. Graft failure in 3 recipients was preceded by subtherapeutic sirolimus exposure in the absence of measurable tacrolimus trough levels.ConclusionsThe tested transplant protocol restored insulin independence and protected against hypoglycemia after single-donor, marginal-dose islet transplantation in 8 of 8 recipients. These results may be related to improved islet engraftment secondary to peritransplant administration of antithymocyte globulin and etanercept. These findings may have implications for the ongoing transition of islet transplantation from clinical investigation to routine clinical care.

19 February 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BHBernhard J Hering
Bernhard J Hering
MWMartin Wijkstrom
Martin Wijkstrom
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
MHMaria Hårdstedt
Maria Hårdstedt
TATor C Aasheim
Tor C Aasheim
HSHenk-Jan Schuurman
Henk-Jan Schuurman

1 March 2004 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
BHBernhard J. Hering
Bernhard J. Hering
RKRaja Kandaswamy
Raja Kandaswamy
JHJames V. Harmon
James V. Harmon
JAJeffrey D. Ansite
Jeffrey D. Ansite
SCSue M. Clemmings
Sue M. Clemmings
JBJeffrey A. Bluestone
Jeffrey A. Bluestone
We sought to determine whether or not optimizing pancreas preservation, islet processing, and induction immunosuppression would facilitate sustained diabetes reversal after single‐donor islet transplants. Islets were isolated from two‐layer preserved pancreata, purified, cultured for 2 days; and transplanted into six C‐peptide‐negative, nonuremic, type 1 diabetic patients with hypoglycemia unawareness. Induction immunosuppression, which began 2 days pretransplant, included the Fc receptor nonbinding humanized anti‐CD3 monoclonal antibody hOKT3γ1 (Ala‐Ala) and sirolimus. Immunosuppression was maintained with sirolimus and reduced‐dose tacrolimus. Of our six recipients, four achieved and maintained insulin independence with normal HbA1c levels and freedom from hypoglycemia; one had partial islet graft function; and one lost islet graft function 2 weeks post‐transplant. The four insulin‐independent patients showed prolonged CD4+ T‐cell lymphocytopenia; inverted CD4:CD8 ratios; and increases in the percentage of CD4+CD25+ T cells. These cells suppressed the in‐vitro proliferative response to donor cells and, to a lesser extent, to third‐party cells. Severe adverse events were limited to a transient rash in one recipient and to temporary neutropenia in three. Our preliminary results thus suggest that a combination of maximized viable islet yield, pretransplant islet culture, and preemptive immunosuppression can result in successful single‐donor islet transplants.

12 May 2015 in Diabetes Care
Verified
Journal Article
Open access
PDF file
PCPratik Choudhary
Pratik Choudhary
MRMichael R. Rickels
Michael R. Rickels
PSPeter A. Senior
Peter A. Senior
MVMarie-Christine Vantyghem
Marie-Christine Vantyghem
PMPaola Maffi
Paola Maffi
BHBernhard J. Hering
Bernhard J. Hering
Problematic hypoglycemia, defined as two or more episodes per year of severe hypoglycemia or as one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior, is a challenge, especially for patients with long-standing type 1 diabetes. Individualized therapy for such patients should include a composite target: optimal glucose control without problematic hypoglycemia. Therefore, we propose a tiered, four-stage algorithm based on evidence of efficacy given the limitations of educational, technological, and transplant interventions. All patients with problematic hypoglycemia should undergo structured or hypoglycemia-specific education programs (stage 1). Glycemic and hypoglycemia treatment targets should be individualized and reassessed every 3–6 months. If targets are not met, one diabetes technology—continuous subcutaneous insulin infusion or continuous glucose monitoring—should be added (stage 2). For patients with continued problematic hypoglycemia despite education (stage 1) and one diabetes technology (stage 2), sensor-augmented insulin pumps preferably with an automated low-glucose suspend feature and/or very frequent contact with a specialized hypoglycemia service can reduce hypoglycemia (stage 3). For patients whose problematic hypoglycemia persists, islet or pancreas transplant should be considered (stage 4). This algorithm provides an evidence-informed approach to resolving problematic hypoglycemia; it should be used as a guide, with individual patient circumstances directing suitability and acceptability to ensure the prudent use of technology and scarce transplant resources. Standardized reporting of hypoglycemia outcomes and inclusion of patients with problematic hypoglycemia in studies of new interventions may help to guide future therapeutic strategies.

10 August 2004 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
NKNicole Kirchhof
Nicole Kirchhof
SSSatoshi Shibata
Satoshi Shibata
MWMartin Wijkstrom
Martin Wijkstrom
DKDavid M. Kulick
David M. Kulick
CSChristopher T. Salerno
Christopher T. Salerno
BHBernhard J. Hering
Bernhard J. Hering